Cell line · CVCL_1495
Papers51
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. | Nat Cell Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer. | Proc Natl Acad Sci U S A | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5. | Oncogenesis | 2023 | Its Methods give the RRID and name the line | PubMed | |
| TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. | Pharmaceuticals (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1495/papers